1. Home
  2. NGNE vs TRTX Comparison

NGNE vs TRTX Comparison

Compare NGNE & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$34.41

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo TPG RE Finance Trust Inc.

TRTX

TPG RE Finance Trust Inc.

HOLD

Current Price

$8.65

Market Cap

659.4M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
TRTX
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
659.4M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
TRTX
Price
$34.41
$8.65
Analyst Decision
Strong Buy
Buy
Analyst Count
7
4
Target Price
$63.57
$9.83
AVG Volume (30 Days)
310.4K
687.8K
Earning Date
05-08-2026
04-28-2026
Dividend Yield
N/A
11.55%
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$8.78
Revenue Next Year
N/A
$4.14
P/E Ratio
N/A
$14.82
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$7.57
52 Week High
$43.66
$9.85

Technical Indicators

Market Signals
Indicator
NGNE
TRTX
Relative Strength Index (RSI) 47.61 55.74
Support Level $18.24 $8.59
Resistance Level $37.27 $8.73
Average True Range (ATR) 3.04 0.16
MACD -0.65 0.01
Stochastic Oscillator 17.67 67.00

Price Performance

Historical Comparison
NGNE
TRTX

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About TRTX TPG RE Finance Trust Inc.

TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.

Share on Social Networks: